Breaking Finance News

TheStreet upgraded Quidel Corporation (NASDAQ:QDEL) to C- in a report released today.

TheStreet has upgraded Quidel Corporation (NASDAQ:QDEL) to C- in a report released on 4/18/2017.

Yesterday Quidel Corporation (NASDAQ:QDEL) traded 0.04% higher at $23.78. The company’s 50-day moving average is $22.12 and its 200-day moving average is $21.23. The last stock close price is up 12.00% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 79,281 shares of the stock were exchanged, down from an average trading volume of 138,750

See Chart Below

Quidel Corporation (NASDAQ:QDEL)

Quidel Corporation has a 52 week low of $15.15 and a 52 week high of $23.94 The company’s market cap is currently $0.

In addition to TheStreet reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $20.42 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Quidel Corporation (NASDAQ:QDEL)

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women's health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.